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Antihypertensive	monotherapy	 is	 often	 insufficient	 to	 control	 blood	 pressure	 (BP).	
Several	recent	guidelines	advocate	for	 initial	combination	drug	therapy	in	many	pa-
tients.	This	meta-	analysis	of	seven	randomized,	double-	blind	studies	(N	=	5888)	evalu-


















the	 Eighth	Joint	National	Committee	 (JNC	8),2	American	 Society	 of	
Hypertension	 (ASH)/International	 Society	 of	 Hypertension	 (ISH),3 




[CKD],	 diabetes	mellitus,	 or	 history	of	 cardiovascular	 disease)	 and	 a	
target	BP	goal	of	<150/90	mm	Hg	for	older	patients	(aged	≥60	years).
The	options	for	treatment	are	generally	well	established.	General	
recommendations	 from	 JNC	 8,	 ASH/ISH,	 and	 ESH/ESC	 for	 initial	
pharmacologic	therapy	choices	after	the	failure	of	 lifestyle	 interven-
tions	 include	 angiotensin-	converting	 enzyme	 inhibitors,	 angiotensin	
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tions	 from	treatment	guidelines	and	clinical	 trials,	 the	current	meta-	
analysis	sought	to	compare	the	efficacy	and	safety	of	OM	single-	pill	
dual-	combination	 therapy	 with	 that	 of	 OM	 monotherapy.	 Analyses	
were	performed	in	the	following	subgroups	of	patients	with	hyperten-
sion:	elderly,	nonelderly,	CKD,	and	non-	CKD.
2  | MATERIALS AND METHODS
2.1 | Database definition and inclusion criteria
An	 integrated	 database	 of	 previously	 locked	 individual	 OM	 clinical	
trial	databases	was	developed	by	Daiichi	Sankyo,	Inc.	(Edison,	NJ)	for	
the	 purpose	 of	 completing	 a	 patient-	level	meta-	analysis.	 The	meta-	
analysis	 included	 completed	 studies	 sponsored	by	 group	 companies	




the	entire	period	of	parallel	design	or	 for	 the	 first	crossover	period.	
To	be	included	in	the	meta-	analysis,	the	studies	had	to	have	a	double-	
blind	 period	 of	 at	 least	 8	weeks	 including	 patients	 (aged	 ≥18	years)	
with	hypertension	in	which	randomized	treatment	consisted	of	either	
OM	single-	pill	dual-	combination	therapy	with	amlodipine,	azelnidipine,	







included	 seated	 systolic	 BP	 [SeSBP]	 and	 seated	 diastolic	 BP)	 and	
change	from	baseline	in	mean	SeBP	at	each	time	point	(observed	case	




treatment-	emergent	adverse	event	 (TEAE)	occurring	within	 the	 first	
8	weeks	of	the	double-	blind	period	or	until	permanent	discontinuation	











tion	 rate	 ≥60	mL/min/1.73	m2).	 For	 subgroup	 analyses	 of	 elderly/
nonelderly	patients	 and	 those	with	 and	without	CKD,	 studies	were	
excluded	if	they	did	not	include	both	subgroups	for	direct	comparison	
within	studies.	Frequency	distributions	and	summary	statistics	for	the	











The	 integrated	 database	 consisted	 of	 53	 trials	 completed	 between	
1996	 and	 2012	 and	 represented	 34	320	 patients.	 Seven	 studies	
were	 included	 in	 the	meta-	analysis	according	 to	 the	 inclusion	crite-
ria	previously	stated	(Figure	S1	and	Table	S1).10,17-21	The	full	analysis	
set	 comprised	 5888	patients	 (OM	dual-	combination	 therapy	 group,	
n	=	3969;	OM	monotherapy	group,	n	=	1919).	Apparent	differences	
between	 the	 baseline	 characteristics	 of	 the	 OM	 dual-	combination	
therapy	and	OM	monotherapy	groups	were	small	(Table	1);	most	pa-
tients	were	men	and	white	with	a	mean	(SD)	age	of	54.8	(10.7)	years,	




The	 demographics	 of	 individual	 subgroups	 mostly	 mirrored	 the	
characteristics	of	the	full	analysis	set	with	the	exception	of	the	elderly	





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1312  |     DEEDWANIA Et Al.













changes	 from	 baseline	 at	 end	 point	 were	 −22.7/−15.0	mm	Hg	 and	
−16.0/−11.3	mm	Hg	 (Figure	2A	 and	 Figure	 S3A).	 The	 analysis	 of	
covariance	 of	 the	 absolute	 mean	 SeSBP	 change	 from	 baseline	 to	
end	 point	 showed	 an	 estimated	 overall	 treatment	 difference	 of	
6.67	mm	Hg	(95%	confidence	interval	[CI],	5.87–7.46)	in	favor	of	OM	
dual-	combination	therapy	(Figure	S4A).
3.2.2 | Elderly and nonelderly subgroups
The	 elderly	 and	 nonelderly	 subgroups	 comprised	 1901	 (OM	 dual-	
combination	therapy,	n	=	1314;	OM	monotherapy,	n	=	587)	and	3947	
(OM	dual-	combination	therapy,	n	=	2631;	OM	monotherapy,	n	=	1316)	
patients,	 respectively.	 Similar	 to	 the	 full	 analysis	 set,	mean	SeBP	was	
lower	 in	 the	OM	dual-	combination	 therapy	 vs	 the	OM	monotherapy	
groups	 at	 end	 point,	 irrespective	 of	 the	 age	 subgroup	 (elderly:	 dual-	 
combination	 therapy,	 141.1/85.4	mm	Hg;	 monotherapy,	 147.7/88.6 
mm	Hg;	 nonelderly:	 dual-	combination	 therapy,	 135.7/86.4	mm	Hg;	
monotherapy,	 142.7/90.5	mm	Hg)	 (Figure	1B,	 Figure	1C,	 Figure	 S2B,	
and	 Figure	 S2C).	Mean	 SeBP	 changes	 from	 baseline	 at	 end	 point	 in	
the	 two	 treatment	 arms	were	 also	 comparable	between	 the	 two	age	











3.2.3 | CKD and non- CKD subgroups
Of	all	patients	in	the	full	analysis	set,	642	had	CKD	(OM	dual-	combination	
therapy,	n	=	428;	OM	monotherapy,	n	=	214)	and	5245	patients	were	
assigned	 to	 the	 non-	CKD	 subgroup	 (OM	 dual-	combination	 therapy,	
n	=	3540;	OM	monotherapy,	n	=	1705).	At	study	end,	mean	SeBP	was	
lower	 among	patients	 receiving	OM	dual-	combination	 therapy	 com-
pared	with	OM	monotherapy	 (Figure	1D,	Figure	1E,	Figure	S2D,	and	
Figure	S2E).	Mean	SeSBP	at	end	point	was	higher	in	the	CKD	subgroup	
(OM	 dual-	combination	 therapy,	 141.8	mm	Hg;	 OM	 monotherapy,	
152.4	mm	Hg)	than	in	the	non-	CKD	subgroup	(OM	dual-	combination	
therapy,	137.0	mm	Hg;	OM	monotherapy,	143.4	mm	Hg).	Compared	
with	 OM	 monotherapy,	 mean	 SeBP	 changes	 from	 baseline	 were	
greater	among	patients	receiving	OM	dual-	combination	therapy	in	both	
the	CKD	and	non-	CKD	subgroups.	While	the	results	for	the	CKD	and	
non-	CKD	 subgroups	 receiving	OM	monotherapy	were	 similar	 (CKD,	
−14.9	mm	Hg;	non-	CKD,	−16.1	mm	Hg),	the	mean	SeBP	change	from	




















More	 nonelderly	 vs	 elderly	 patients	 receiving	 OM	 dual-	
combination	 therapy	achieved	an	SeBP	goal	of	<140/90	mm	Hg	at	
end	point	(53.5%	vs	47.1%,	respectively)	(Figure	3A).	A	greater	pro-
portion	 of	 patients	 receiving	OM	 dual-	combination	 therapy	 in	 the	
non-	CKD	 subgroup	 achieved	 the	 SeBP	 goal	 of	 <140/90	mm	Hg	



























































































     OM Mono: n=
      OM Dual:  n =
1919 1062 1869 631 1755
3969 2121 3888 1300 3678
OM Mono: EP (LOCF)
[144.4 mm Hg]
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587 332 571 196 542
1314 701 1284 436 1215
OM Mono: EP (LOCF)
[147.7 mm Hg]
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1316 716 1283 427 1198
2631 1403 2581 857 2443
OM Mono: EP (LOCF)
[142.7 mm Hg]
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125 109 115 96 106
260 233 238 204 225
OM Mono: EP (LOCF)
[156.5 mm Hg]















     OM Mono: n=










477 368 447 328 418
941 720 902 671 845
OM Mono: EP (LOCF)
[145.2 mm Hg]
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groups	 (28.9%	 vs	 29.8%,	 respectively)	 (Table	2).	 The	 occurrence	
of	serious	TEAEs	was	also	similar	between	groups	 (0.7%	for	both),	
whereas	the	proportions	of	patients	with	drug-	related	TEAEs	were	
higher	 in	 the	 OM	 dual-	combination	 therapy	 group	 than	 in	 the	
monotherapy	group	(10.2%	vs	8.7%,	respectively).	No	deaths	were	
observed.	 The	 most	 frequently	 observed	 TEAEs	 were	 peripheral	
edema,	 headache,	 nasopharyngitis,	 dizziness,	 edema,	 fatigue,	 and	



















































































     OM Mono: n=
OM Dual: n=
1062 1869 631 1755
2121 3888 1300 3678
OM Dual: EP (LOCF)
[−22.7 mm Hg]
OM Mono: EP (LOCF)
[−16.0 mm Hg]
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     OM Mono: n=
      OM Dual:  n =
332 571 196 542
701 1284 436 1215
OM Dual: EP (LOCF)
[−22.8 mm Hg]
OM Mono: EP (LOCF)
[−17.1 mm Hg]
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     OM Mono: n=
      OM Dual:  n =
716 1283 427 1198
1403 2581 857 2443
OM Dual: EP (LOCF)
[−22.6 mm Hg]
OM Mono: EP (LOCF)
[−15.4 mm Hg]
C








































     OM Mono: n=
      OM Dual:  n =
109 115 96 106
233 238 204 225
OM Dual: EP (LOCF)
[−24.5 mm Hg]
OM Mono: EP (LOCF)
[−7.6 mm Hg]
D









































     OM Mono: n=
      OM Dual:  n =
368 447 328 418
720 902 671 845
OM Dual: EP (LOCF)
[−26.5 mm Hg]
OM Mono: EP (LOCF)
[−15.9 mm Hg]
E
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low	and	similar	between	the	OM	dual-	combination	therapy	and	OM	
monotherapy	groups.
3.4.2 | Elderly and nonelderly subgroups
In	the	elderly	subgroup,	the	incidence	of	any	TEAE	was	lower	in	the	OM	











3.4.3 | CKD and non- CKD subgroups
In	the	CKD	subgroup,	the	incidence	of	any	TEAE	was	higher	in	the	OM	
monotherapy	group	than	in	the	OM	dual-	combination	therapy	group	








Hypertension	 guidelines	 generally	 recommend	 starting	 patients	
with	 hypertension	 on	monotherapy,	with	 treatment	 options	 includ-
ing	 angiotensin-	converting	 enzyme	 inhibitors,	 ARBs,	 calcium	 chan-
nel	blockers,	 thiazide-	type	diuretics,	or	a	β-	blocker.	Guidelines	 such	
as	those	from	ASH/ISH	provide	advice	on	specific	drug	selection	by	
patient	 type.3	 If	 the	 initial	 treatment	 is	not	sufficient	 to	achieve	BP	
goals,	patients	may	be	prescribed	a	higher	dose	of	monotherapy	up	
to	a	maximum	dose	or	will	need	a	second	agent	from	a	different	drug	








Despite	 slight	 variations	 in	 efficacy	 among	 the	 different	 pa-
tient	 populations	 examined	 in	 this	 meta-	analysis,	 both	 OM	 dual-	
combination	 therapy	and	OM	monotherapy	achieved	substantial	BP	
reductions	after	2	weeks	of	treatment,	which	were	maintained	through	




vious	meta-	analysis	 by	Wald	 and	 colleagues,22	which	 demonstrated	
the	superior	BP-	lowering	efficacy	of	combination	therapy.	Moreover,	




on	monotherapy.23	 In	 light	of	 these	findings,	 initiating	antihyperten-
sive	treatment	with	combination	therapy	may	be	preferred	over	initi-
ating	treatment	with	a	single	agent	alone.
The	 prevalence	 of	 hypertension	 increases	with	 age,	 being	 pres-
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1919 587 1316 214 1705
3969 1314 2631 428 3540
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numerically	 similar	 SeSBP	 reductions	 compared	with	 nonelderly	 pa-
tients.	Additional	supplemental	analyses	demonstrated	similar	trends	
in	 the	 efficacy	 of	 OM	 dual-	combination	 therapy	 and	 monotherapy	
among	patients	70	years	and	older	vs	those	60	years	and	older.	Taken	






full	 analysis	 set,	OM	dual-	combination	 therapy	was	 associated	with	




A	 previous	meta-	analysis	 by	Wang	 and	 colleagues27	 showed	 no	
association	 between	 OM	 and	 an	 increased	 risk	 of	 adverse	 events	
compared	with	other	ARBs	(losartan,	candesartan,	valsartan,	and	irbe-
sartan).	 In	 the	 current	 analysis,	 both	OM	dual-	combination	 therapy	
and	OM	monotherapy	were	well	 tolerated	 in	 all	 patients	 examined,	
and	there	were	no	unexpected	safety	concerns.	A	higher	proportion	
of	TEAEs	and	drug-	related	TEAEs	was	reported	in	the	CKD	subgroup	







SPRINT	 (Systolic	 Blood	 Pressure	 Intervention	Trial)	 study	 demon-




over	 those	patients	 treated	 to	 the	more	 conservative	 goal	 (2.8	vs	
1.8	 medications,	 respectively).28	 The	 HOPE-	3	 (Heart	 Outcomes	







5  | STUDY STRENGTHS AND LIMITATIONS
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